Dallas, TX -- (SBWire) -- 11/23/2010 -- SandlerResearch announce Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

GBI Research’s Therapeutic Analysis report, “Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.

Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).

Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.

Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.

Key drivers and barriers that have a significant impact on the market.

Coverage of pipeline molecules in various phases of drug development.

Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.

Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to:

Align your product portfolio to the markets with high growth potential.

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

Develop key strategic initiatives by understanding the key focus areas of leading companies.

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Global Urological Disorders Market: Introduction 10
2.1 GBI Research Report Guidance 11
3 Global Urological Disorders Market: Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Global Urological Disorders Market 13
3.2.1 Sales Value 13
3.2.2 Annual Cost of Therapy 14
3.2.3 Treatment Usage Patterns 15
3.2.4 Generics’ Share in the Global Urological Disorders Market 20
3.3 Urological Disorders Market Drivers 22
3.3.1 Steady Increase in the UI and BPH Prevalence Population 22
3.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH 22
3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 22
3.4 Urological Disorders Market Restraints 23
3.4.1 Unwillingness to Seek Medical Help for UI 23
3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues 23
3.4.3 Non Pharmacological Therapy Recommended for UI and BPH 23
4 Global Urological Disorders Market: Therapeutic Landscape 24
4.1 Benign Prostatic Hyperplasia Market 24
4.1.1 Introduction 24
4.1.2 Sales Value 24
4.1.3 Annual Cost of Therapy 26
4.1.4 Treatment Usage Patterns 27
4.1.5 Market Share by Geography 32
4.1.6 Generics’ Share of the Global BPH Market 35
4.2 Urinary Incontinence (UI) Market 36
4.2.1 Introduction 36
4.2.2 Sales Value 37
4.2.3 Annual Cost of Therapy 39
4.2.4 Treatment Usage Patterns 40
4.2.5 Market Share by Geography 45
4.2.6 Generics’ Share in the Global UI Market 49
4.3 Urinary Tract Infections Market 51
4.3.1 Introduction 51
4.3.2 Sales Value 51
4.3.3 Annual Cost of Therapy 53
4.3.4 Treatment Usage Patterns 54
4.3.5 Market Share by Geography 59
4.3.6 Generics’ Share of the Global UTI Market 62
5 Global Urological Disorders Market: Geographical Landscape 64
5.1 Geographical Break-up 64
5.2 The US 67
5.2.1 Sales Value 67
5.2.2 Annual Cost of Therapy 68
5.2.3 Treatment Usage Patterns 69
5.3 Top Five Countries in Europe 75
5.3.1 Sales Value 75
5.3.2 Annual Cost of Therapy 76
5.3.3 Treatment Usage Patterns 77
5.4 Japan 83
5.4.1 Sales Value 83
5.4.2 Annual Cost of Therapy 84
5.4.3 Treatment Usage Patterns 85
6 Global Urological Disorders Market: Pipeline Analysis 90
6.1 Introduction 90
6.1.1 Research and Development Pipeline – UI 91
6.1.2 Research and Development Pipeline – BPH 93
6.1.3 Research and Development Pipeline – UTI 95
6.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 97
6.2.1 Botulinum Toxin A 97
6.2.2 YM178 98
6.2.3 NX-1207 98
6.2.4 PRX302 99
6.2.5 NXL104/ceftazidime 100
7 Global Urological Disorders Market: Competitive Landscape 101
7.1 Market Share Analysis: Urological Disorders 101
7.2 Competitive Profiling 103
7.2.1 Astellas Pharma 103
7.2.2 Johnson and Johnson (J&J) 104
7.2.3 Pfizer 106
7.2.4 GlaxoSmithKilne (GSK) 107
7.2.5 Sanofi-Aventis 108
8 Global Urological Disorders Market: Strategic Consolidations 110
8.1 Overview 110
8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 112
8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 112
8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 112
8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 112
8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 112
8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 112
8.2 R&D Licensing Agreements 113
8.2.1 Deals by Indication 113
8.2.2 Deals by Phase 114
8.2.3 Deals by Geography 114
8.2.4 Deals by Licensing Type 115
8.2.5 Deals by Value ($) 115
8.2.6 Phase I 116
8.2.7 Phase II 117
8.2.8 Approved 118
9 Global Urological Disorders Market: Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 121
9.3.3 Primary Research 122
9.3.4 Forecasts 122
9.3.5 Expert Panel Validation 124
9.4 Contact Us 125
9.5 Disclaimer 125
9.6 Sources 125

ABBREVIATIONS

Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/

Browse all : GBI Research
http://www.sandlerresearch.org/publishers/gbi-research/

Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx

Related Reports :

Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth
http://www.sandlerresearch.org/Reports/8519-pipeline-insight-benign-prostatic-hyperplasia-novel-therapeuti.html

The UK Medical Devices Industry: Increasing Incidence of Lifestyle Disorders Driving Growth
http://www.sandlerresearch.org/Reports/25490-the-uk-medical-devices-industry-increasing-incidence-of-lifestyl.html

Disease and Therapy Review: Urinary Incontinence
http://www.sandlerresearch.org/Reports/23223-disease-and-therapy-review-urinary-incontinence.html

Tissue Heart Valves: Aging Population in the US and Europe Bolstering Growth
http://www.sandlerresearch.org/Reports/14991-tissue-heart-valves-aging-population-in-the-us-and-europe-bolste.html

Dental Implants Market: Increasing Clinical Familiarity to Drive Growth
http://www.sandlerresearch.org/Reports/15322-dental-implants-market-increasing-clinical-familiarity-to-drive-.html

About Sandler Research
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.

Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.

We also provide 24/7 online and offline support to our customers

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/

Original Source : Urological Disorder Therapeutic Market
http://www.sandlerresearch.org/reports/33050-urological-disorders-therapeutics-to-2016-increasing-awareness-.html

Buy Now : Market Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pipeline-analysis-and-mark.html

Browse complete Report at : Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

http://www.sandlerresearch.org/reports/33050-urological-disorders-therapeutics-to-2016-increasing-awareness-.html